Novartis to Buy Regulus Therapeutics for as Much as $1.7 Billion

Novartis AG agreed to buy US biotech Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion.

The Swiss company will pay $7 a share in cash upfront through a subsidiary, equivalent to $800 million, according to a statement Wednesday.